surrogate virus neutralizing test genscript cpasstm  (GenScript corporation)

Journal: bioRxiv

Article Title: SARS-CoV-2 exposure in wild white-tailed deer ( Odocoileus virginianus )

doi: 10.1101/2021.07.29.454326

Figure Lengend Snippet:

Article Snippet: Samples were tested using the species and isotype independent Genscript cPassTM surrogate virus neutralization test (sVNT) in an ELISA format.

Techniques: Virus, Neutralization

Journal: bioRxiv

Article Title: SARS-CoV-2 exposure in wild white-tailed deer ( Odocoileus virginianus )

doi: 10.1101/2021.07.29.454326

Figure Lengend Snippet: Serum samples were tested using the Genscript cPass™ surrogate virus neutralization test (sVNT).

Article Snippet: Samples were tested using the species and isotype independent Genscript cPassTM surrogate virus neutralization test (sVNT) in an ELISA format.

Techniques: Virus, Neutralization

Journal: Journal of Virological Methods

Article Title: Evaluation of a surrogate virus neutralization test for high-throughput serosurveillance of SARS-CoV-2

doi: 10.1016/j.jviromet.2021.114228

Figure Lengend Snippet: Sensitivity of the different serological tests and cut-offs used based on the final serum panels. Values between brackets represent 95 % confidence intervals on the estimations.

Article Snippet: Here, we performed an independent evaluation of a commercially available surrogate virus neutralization test (sVNT, GenScript cPassTM) that can be done without biosafety level 3 containment in less than 2 h. When using the cVNT and a Luminex multiplex immunoassay (MIA) as reference, the sVNT obtained a sensitivity of 94 % (CI 90–96 %) on a panel of 317 immune sera that were obtained from hospitalized and mild COVID-19 cases from Belgium and a sensitivity of 88 % (CI 81–93 %) on a panel of 184 healthcare workers from the Democratic Republic of Congo.

Techniques: Luminex

Journal: Journal of Virological Methods

Article Title: Evaluation of a surrogate virus neutralization test for high-throughput serosurveillance of SARS-CoV-2

doi: 10.1016/j.jviromet.2021.114228

Figure Lengend Snippet: Correlations between the percentage of inhibition measured by the surrogate viral neutralisation test (sVNT) and the log(dilution factors or signal-to-noise ratio) for the conventional viral neutralization test (cVNT) or the Luminex multiplex immunological assay (MIA) as calculated by the nonparametric Spearman correlation test (r s ). Seropositivity cut-off levels for the sVNT are indicated by the dashed grey lines at 20 or 30 % inhibition. Negative samples on the cVNT or MIA were not included in these figures.

Article Snippet: Here, we performed an independent evaluation of a commercially available surrogate virus neutralization test (sVNT, GenScript cPassTM) that can be done without biosafety level 3 containment in less than 2 h. When using the cVNT and a Luminex multiplex immunoassay (MIA) as reference, the sVNT obtained a sensitivity of 94 % (CI 90–96 %) on a panel of 317 immune sera that were obtained from hospitalized and mild COVID-19 cases from Belgium and a sensitivity of 88 % (CI 81–93 %) on a panel of 184 healthcare workers from the Democratic Republic of Congo.

Techniques: Inhibition, Neutralization, Luminex, Multiplex Assay